US Stock MarketDetailed Quotes
ADVM Adverum Biotechnologies
- 9.3900
- -0.8000-7.85%
Close Apr 25 16:00 ET
- 9.5700
- +0.1800+1.92%
Post 17:17 ET
194.89MMarket Cap-809P/E (TTM)
10.2150High9.3400Low847.54KVolume10.2000Open10.1900Pre Close8.18MTurnover7.23%Turnover RatioLossP/E (Static)20.75MShares29.700052wk High2.34P/B110.04MFloat Cap7.210052wk Low--Dividend TTM11.72MShs Float624.8000Historical High--Div YieldTTM8.59%Amplitude5.3100Historical Low9.6560Avg Price1Lot Size
Adverum Biotechnologies Stock Forum
Sign in to post a comment
Update
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
1
2
Sold half at 1.8 but chart look good
$Adverum Biotechnologies(ADVM.US$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
1
1
Let’s see.
$Adverum Biotechnologies(ADVM.US$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
1
feels like insider action.
$Adverum Biotechnologies(ADVM.US$ I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.
Dr. Corbau's appointment, with his gene therapy expertise, is seen as crucial for Adverum's Ixo-vec advancement towards pivotal trials and commercialization for treating wet AMD. He is eager to progress Adverum's early-stage research assets and sees Ixo-vec as a potential leading therapy for wet AMD.
Ph2 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
23
Was taking this bit of Grrr time in market to look at some notes. Found this and ima share. Hehehe
$Adverum Biotechnologies(ADVM.US$ Seems DATA date is coming on 2/8/24? May be time if you dont have a position that your making a bit of profit from? To be looking for a ST? Or make yourself a note/reminder. Just thinking outloud! Hehehe
Screenshot of my note to help you make a note! Use your tools available to make you a successful trader
Screenshot of my note to help you make a note! Use your tools available to make you a successful trader
1
4
Upcoming Ph 2 readouts in Q1 2024…
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
New!
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients With Wet AMD at AAO 2023
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden -
- 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 ...
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden -
- 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 ...
1
2
UPDATE!
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Reports Aflibercept Protein Level Data From LUNA Phase 2 Trial; Says Ixo-vec Has Been Well Tolerated With Favorable Preliminary Safety Profile
1
2
. Let’s hold for longer!No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
QianmengYu : nice!
QianmengYu : drop to halt. Hmmm